# CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients

> **NCT00526643** · PHASE3 · TERMINATED · sponsor: **National Cancer Institute, Naples** · enrollment: 57 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00526643
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** scarce enrolment and presentation of positive results of similar study in June 2012.
- **Last updated:** 2017-03-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00526643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00526643, "CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00526643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*